KR20040084929A - 부분적이거나 완전한 ａ1 아데노신 수용체의 작용제 - Google Patents

부분적이거나 완전한 ａ1 아데노신 수용체의 작용제 Download PDF

Info

Publication number
KR20040084929A
KR20040084929A KR10-2004-7012954A KR20047012954A KR20040084929A KR 20040084929 A KR20040084929 A KR 20040084929A KR 20047012954 A KR20047012954 A KR 20047012954A KR 20040084929 A KR20040084929 A KR 20040084929A
Authority
KR
South Korea
Prior art keywords
tetrahydrofuran
optionally substituted
diol
compound
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7012954A
Other languages
English (en)
Korean (ko)
Inventor
이브라힘프라바
엘제인엘파티
셍크케빈
장로버트
자블록키제프
리샤오펀
모리슨크리스토퍼
페리타오
샤오덩밍
Original Assignee
씨브이 쎄러퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨브이 쎄러퓨틱스, 인코포레이티드 filed Critical 씨브이 쎄러퓨틱스, 인코포레이티드
Publication of KR20040084929A publication Critical patent/KR20040084929A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR10-2004-7012954A 2002-02-19 2003-02-19 부분적이거나 완전한 ａ1 아데노신 수용체의 작용제 Ceased KR20040084929A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35796102P 2002-02-19 2002-02-19
US60/357,961 2002-02-19
PCT/US2003/007289 WO2003070739A1 (en) 2002-02-19 2003-02-19 Partial and full agonists of a1 adenosine receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020107006113A Division KR101032005B1 (ko) 2002-02-19 2003-02-19 부분적이거나 완전한 ａ1 아데노신 수용체의 작용제

Publications (1)

Publication Number Publication Date
KR20040084929A true KR20040084929A (ko) 2004-10-06

Family

ID=27757687

Family Applications (2)

Application Number Title Priority Date Filing Date
KR10-2004-7012954A Ceased KR20040084929A (ko) 2002-02-19 2003-02-19 부분적이거나 완전한 ａ1 아데노신 수용체의 작용제
KR1020107006113A Expired - Fee Related KR101032005B1 (ko) 2002-02-19 2003-02-19 부분적이거나 완전한 ａ1 아데노신 수용체의 작용제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107006113A Expired - Fee Related KR101032005B1 (ko) 2002-02-19 2003-02-19 부분적이거나 완전한 ａ1 아데노신 수용체의 작용제

Country Status (15)

Country Link
US (3) US7144871B2 (https=)
EP (2) EP1476455A1 (https=)
JP (1) JP2005527502A (https=)
KR (2) KR20040084929A (https=)
CN (2) CN1636009A (https=)
AU (2) AU2003223237C1 (https=)
CA (1) CA2476683C (https=)
IL (2) IL163613A0 (https=)
MX (1) MXPA04008008A (https=)
NO (1) NO330243B1 (https=)
NZ (1) NZ534801A (https=)
PL (1) PL372145A1 (https=)
RU (1) RU2317994C2 (https=)
WO (1) WO2003070739A1 (https=)
ZA (1) ZA200406607B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) * 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
WO2003070739A1 (en) * 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
DE102004032651A1 (de) * 2004-07-06 2006-02-16 Bayer Healthcare Ag Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
EP1768991A1 (en) * 2004-07-12 2007-04-04 Cv Therapeutics, Inc. Process for the preparation of a1-adenosine receptor agonists
RU2443708C2 (ru) * 2007-05-17 2012-02-27 Си Ви Терапьютикс, Инк. Способ получения агониста рецептора a2a-аденозина и его полиморфных модификаций
US20130123345A1 (en) * 2010-07-23 2013-05-16 The Ohio State University Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway
JP2015172077A (ja) * 2015-06-24 2015-10-01 中国医学科学院葯物研究所 Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
PE20181894A1 (es) 2016-03-10 2018-12-11 Janssen Pharmaceutica Nv Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5
TN2018000310A1 (en) 2016-03-10 2020-01-16 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
MA46228A (fr) 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN115626935B (zh) 2016-10-03 2025-07-15 詹森药业有限公司 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
BR112019012106A2 (pt) 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
CN110382707A (zh) 2017-02-27 2019-10-25 詹森药业有限公司 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途
IL275129B2 (en) 2017-12-08 2023-10-01 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение
WO2020046403A1 (en) * 2018-08-31 2020-03-05 Muhammed Majeed Novel process for the preparation of enantiopure 3- enantiopure 3-amino tetrahydrofuran and its salts
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
JP7598338B2 (ja) 2019-06-12 2024-12-11 ヤンセン ファーマシューティカ エヌ．ベー． 新規なスピロ二環式中間体
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6576620B2 (en) * 1999-12-03 2003-06-10 Cv Therapeutics, Inc. Method of identifying partial adenosine A1 receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
WO2003070739A1 (en) * 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors

Also Published As

Publication number Publication date
AU2008249143A1 (en) 2008-12-11
US7144871B2 (en) 2006-12-05
RU2004125492A (ru) 2006-01-27
NO330243B1 (no) 2011-03-14
AU2003223237C1 (en) 2009-03-26
ZA200406607B (en) 2006-05-31
US7696181B2 (en) 2010-04-13
AU2003223237A1 (en) 2003-09-09
NZ534801A (en) 2006-04-28
WO2003070739A1 (en) 2003-08-28
AU2008249143B2 (en) 2011-08-25
US20030232783A1 (en) 2003-12-18
KR101032005B1 (ko) 2011-05-02
KR20100046058A (ko) 2010-05-04
CN101392012A (zh) 2009-03-25
NO20043907L (no) 2004-09-17
EP1476455A1 (en) 2004-11-17
JP2005527502A (ja) 2005-09-15
IL163613A0 (en) 2005-12-18
EP2412716A1 (en) 2012-02-01
CN1636009A (zh) 2005-07-06
CA2476683C (en) 2011-11-01
CA2476683A1 (en) 2003-08-28
AU2003223237B2 (en) 2008-08-21
IL163613A (en) 2010-12-30
MXPA04008008A (es) 2005-03-23
US20060287275A1 (en) 2006-12-21
PL372145A1 (en) 2005-07-11
US20090325896A1 (en) 2009-12-31
RU2317994C2 (ru) 2008-02-27

Similar Documents

Publication Publication Date Title
KR101032005B1 (ko) 부분적이거나 완전한 ａ1 아데노신 수용체의 작용제
WO2008077050A1 (en) Adenosine derivatives as partial and full agonists of a1 adenosine receptors
US7271157B2 (en) A1 adenosine receptor agonists
US20090137520A1 (en) A1 adenosine receptor agonists
EP1537133B1 (en) Partial and full agonists of a1 adenosine receptors
HK1130805A (en) Partial and full agonists of a1 adenosine receptors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040819

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080219

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090819

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100212

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090819

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20100319

PJ0201 Trial against decision of rejection

Patent event date: 20100319

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20100212

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20100402

Appeal identifier: 2010101002092

Request date: 20100319

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20100326

WITB Written withdrawal of application
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20100319

Effective date: 20100402

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20100402

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20100319

Decision date: 20100402

Appeal identifier: 2010101002092